Can Targeting Activin-A Unleash the Anti-Cancer Potential of NK Cells?

The human immune system serves as a critical defense against pathogens and abnormal cells. Among its components, natural killer (NK) cells—key players in innate immunity—can directly eliminate senescent, damaged, and cancerous cells without requiring antigen recognition, positioning them as the "first line of defense" in anti-tumor immune responses. However, within the tumor microenvironment (TME), NK cell function is often significantly suppressed, leading to reduced cytotoxic activity. Recently, an Australian research team uncovered the pivotal role of the protein Activin-A in inhibiting NK cell function, offering a novel target for enhancing anti-tumor immunity. The study was published in Science Signaling under the title "Therapeutic blockade of activin-A improves NK cell function and antitumor immunity."

Cover Image from Science Signaling Official Website

1. Why Do NK Cells Become "Inactive" in Tumors?

Although daily activities such as exercise can enhance NK cell activity, tumors employ multiple mechanisms to suppress their function. Similar to T-cell immune checkpoints (e.g., PD-1/PD-L1, LAG-3), NK cells experience functional exhaustion in the TME. Previous studies have shown that NK cell activity positively correlates with cancer patient survival, with highly active NK cells predicting better prognosis. However, the mechanisms underlying their suppression remain incompletely understood.

2. Activin-A: How Was This Novel NK Cell Suppressor Discovered?

The research team led by Dr. Jai Rautela and Professor Nicholas Huntington at Monash University, Australia, discovered that the protein Activin-A significantly inhibits NK cell proliferation and cytotoxic function. Experiments demonstrated that Activin-A impairs NK cell activation and survival, thereby reducing their ability to clear tumor cells.
Notably, this pathway operates independently of known immunosuppressive mechanisms (e.g., PD-1/PD-L1), representing a novel immune escape route.

3. Can Targeting Activin-A Restore NK Cell Function?

The study further explored intervention strategies targeting Activin-A. Using the approved drug Follistatin to block Activin-A, NK cell function was significantly restored. In a humanized melanoma mouse model, inhibiting Activin-A markedly delayed tumor progression and enhanced NK cell-mediated anti-tumor immune responses.
This finding suggests that targeting Activin-A could become a new strategy to complement existing immunotherapies (e.g., immune checkpoint inhibitors), particularly for patient populations that respond poorly to current treatments.

4. Why Is NK Cell-Targeted Therapy a Promising New Direction in Cancer Treatment?

NK cell-based immunotherapies (e.g., CAR-NK) have already demonstrated clinical potential. The Activin-A blockade strategy proposed in this study offers new avenues for restoring endogenous NK cell function or optimizing adoptive NK cell therapies. By combining multi-mechanistic and multi-cellular immunoregulatory approaches, a more comprehensive activation of anti-tumor immune responses may be achieved, improving patient outcomes and reducing recurrence risks.
Future research should further elucidate the regulatory mechanisms of Activin-A expression in human tumor microenvironments and advance related inhibitors into clinical translational studies.